Published in Health Business Week, December 31st, 2004
The company also announced that the underwriters of this offering exercised in full their option to purchase an additional 1,397,500 shares of Cubist common stock at $11.20 per share. Gross proceeds of approximately $120 million represent a 20% increase over the original shelf registration statement previously filed with the U.S. Securities and Exchange Commission.
Proceeds to Cubist from this offering, net of underwriting discounts and commissions, and estimated offering expenses, totaled $112.5...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.